Welcome to the InfoSci Platform
Productive Development Partnership in Brazil: A Case Study of the Antiretroviral Atazanavir

Productive Development Partnership in Brazil: A Case Study of the Antiretroviral Atazanavir

Carla Silveira, Wanise Barroso, Marilena C. D. V. Correa
Copyright: © 2022 |Pages: 25
ISBN13: 9781799880110|ISBN10: 1799880117|EISBN13: 9781799880127
DOI: 10.4018/978-1-7998-8011-0.ch014
Cite Chapter Cite Chapter

MLA

Silveira, Carla, et al. "Productive Development Partnership in Brazil: A Case Study of the Antiretroviral Atazanavir." Handbook of Research on Essential Information Approaches to Aiding Global Health in the One Health Context, edited by Jorge Lima de Magalhães, et al., IGI Global, 2022, pp. 262-286. https://doi.org/10.4018/978-1-7998-8011-0.ch014

APA

Silveira, C., Barroso, W., & Correa, M. C. (2022). Productive Development Partnership in Brazil: A Case Study of the Antiretroviral Atazanavir. In J. Lima de Magalhães, Z. Hartz, G. Jamil, H. Silveira, & L. Jamil (Eds.), Handbook of Research on Essential Information Approaches to Aiding Global Health in the One Health Context (pp. 262-286). IGI Global. https://doi.org/10.4018/978-1-7998-8011-0.ch014

Chicago

Silveira, Carla, Wanise Barroso, and Marilena C. D. V. Correa. "Productive Development Partnership in Brazil: A Case Study of the Antiretroviral Atazanavir." In Handbook of Research on Essential Information Approaches to Aiding Global Health in the One Health Context, edited by Jorge Lima de Magalhães, et al., 262-286. Hershey, PA: IGI Global, 2022. https://doi.org/10.4018/978-1-7998-8011-0.ch014

Export Reference

Mendeley
Favorite

Abstract

Brazil was one of the first countries to adopt significant health policies to better attend people with HIV. The integrated analysis of the high cost of medicines, public health, and access to medicines comprises an extremely complex task, and Productive Development Partnerships (PDP) was the mechanism used by the Brazilian government, with a view to technological development and training of national production complex. The PDP of atazanavir was formalized in late 2011, and the agreement includes the transfer of technology, manufacturing, and distribution of the drug. The PDP emerges as a solution found by the government to minimize the Ministry of Health drug spending and encourage the local production. However, one should not ignore that there are risks associated with regulatory barriers and problems in negotiations with the holders of technology. Thus, this chapter presents a case study of the successes the management information of the productive development partnerships in Brazil as a collaborative tool for global health.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.